The purpose of this study is to define and compare the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EYP651 at two dose levels and compare it with Vonafexor Acid PK and PD profile, the Part A. In addition, Part B of the trial will assess the Drug-Drug Interactions (DDI) potential with the high dose of EYP651.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Pharmacokinetic Area Under the Curve (AUC)
Timeframe: 1 day
Part A: Pharmacokinetic Maximum Plasma Concentration (Cmax)
Timeframe: 1 day
Part A: Pharmacokinetic AUC
Timeframe: 5 days
Part A: Pharmacokinetic Cmax
Timeframe: 5 days
Part B: CYP3A4 inhibition change in AUC
Timeframe: 5 days
Part B: CYP3A4 inhibition change in Cmax
Timeframe: 5 days
Part B: Transporter sensitive substrate change in AUC
Timeframe: 5 days
Part B: Transporter sensitive substrate change in Cmax
Timeframe: 5 days
Part B: CYP2C8/CYP2C9 sensitive substrate change in AUC
Timeframe: 5 days
Part B: CYP2C8/CYP2C9 sensitive substrate change in Cmax
Timeframe: 5 days